leisure time -WSS

leisure time

author：knowledge 2025-09-28 12:53:28 Page View：769

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Head of FDA's diagnostics center, who led through Covid, retires
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Immunocompromised patients offer clues on chronic Covid

ThiscolorizedelectronmicroscopeimageshowsSARS-CoV-2,indicatedinyellow,emergingfromthesurfaceofcells,

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

To bolster infectious disease surveillance, genomics powerhouses team up

TuliodeOliveiraleadsSouthAfrica’sCentreforEpidemicResponseandInnovation.CourtesyCERI@SULONDON—Twores

leisure time

focus

explore

To bolster infectious disease surveillance, genomics powerhouses team up